Abstract
In this study, a high CD34% in autologous peripheral blood stem cell (PBSC) products from 71 AML patients was associated directly with a high relapse rate (P = 0.006) and inversely with disease-free survival (P = 0.003), irrespective whether patients were transplanted or not. The relapse rate at 12 months was 67% in a group with >0.8% CD34+ cells and 34% in a group with ⩽0.8% CD34+ cells. Although the percentage of malignant CD34+ cells in the CD34+ compartment in the relapses of the first group was not high (median 8%), the total number of malignant cells as a percentage of WBC was about 13 times higher than for the patients remaining >12 months in remission. When all patients evaluable were taken together, this frequency of malignant cells correlated strongly with disease-free survival (P < 0.001). Both this massive mobilization of normal CD34+ cells and high frequency of malignant cells in the subgroup of patients with CD34 >0.8% and relapse within 12 months indicate an insufficient in vivo purging, as well as low chemotherapeutic bone marrow toxicity. This was confirmed by an inverse correlation between hypoplasia period after the induction therapy and CD34% in PBSC products (P < 0.002). It is concluded that a subgroup of patients has been identified that might benefit from a more intensive chemotherapeutic treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Burnett, AK, Goldstone, AH, Stevens, RM, Hann, IM, Rees, JK, Gray, RG & Wheatley, K. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet, (1998). 351, 700–708.
San Miguel, JF, Vidriales, MB, Lopez-Berges, C, Diaz-Mediavilla, J, Gutierrez, N, Canizo, C, Ramos, F, Calmuntia, MJ, Perez, JJ, Gonzalez, M & Orfao, A Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood, (2001). 98, 1746–1751.
Venditti, A, Buccisano, F, Del Poeta, G, Maurillo, L, Tamburini, A, Cox, C, Battaglia, A, Catalano, G, Del Moro, B, Cudillo, L, Postorino, M, Masi, M & Amadori, S Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood, (2000). 96, 3948–3952.
Reichle, A, Rothe, G, Krause, S, Zaiss, M, Ullrich, H, Schmitz, G & Andreesen, R Transplant characteristics: minimal residual disease and impaired megakaryocytic colony growth as sensitive parameters for predicting relapse in acute myeloid leukemia. Leukemia, (1999). 13, 1227–1234.
van Dongen, JJ, Szczepanski, T, de Bruijn, MA, van den Beemd, MW, de Bruin-Versteeg, S, Wijkhuijs, JM, Tibbe, GJ, van Gastel-Mol, EJ, Groeneveld, K & Hooijkaas, H Detection of minimal residual disease in acute leukemia patients. Cytok Mol Ther, (1996). 2, 121–133.
van der Pol, MA, Pater, JM, Feller, N, Westra, AH, van Stijn, A, Ossenkoppele, GJ, Broxterman, HJ & Schuurhuis, GJ Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemia. Leukemia, (2001). 15, 1554–1563.
Campana, D & Pui, CH Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood, (1995). 85, 1416–1434.
Siena, S, Schiavo, R, Pedrazzoli, P & Carlo-Stella, C Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol, (2000). 18, 1360–1377.
Weaver, CH, Potz, J, Redmond, J, Tauer, K, Schwartzberg, LS, Kaywin, P, Drapkin, R, Grant, B, Unger, P, Allen, C, Longin, K, Zhen, B, Hazelton, B & Buckner, CD Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content. Bone Marrow Transplant, (1997). 19, 1103–1110.
Schulman, KA, Birch, R, Zhen, B, Pania, N & Weaver, CH Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol, (1999). 17, 1227
Vellenga, E, van Putten, WL, Boogaerts, MA, Daenen, SM, Verhoef, GE, Hagenbeek, A, Jonkhoff, AR, Huijgens, PC, Verdonck, LF, van der Lelie, J, Schouten, HC, Gmur, J, Wijermans, P, Gratwohl, A, Hess, U, Fey, MF & Lowenberg, B Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?. Bone Marrow Transplant, (1999). 23, 1279–1282.
Grimwade, D, Walker, H, Oliver, F, Wheatley, K, Harrison, C, Harrison, G, Rees, J, Hann, I, Stevens, R, Burnett, A & Goldstone, A The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, (1998). 92, 2322–2333.
Sutherland, DR, Anderson, L, Keeney, M, Nayar, R & Chin-Yee, I The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother, (1996). 5, 213–226.
Lacombe, F, Durrieu, F, Briais, A, Dumain, P, Belloc, F, Bascans, E, Reiffers, J, Boisseau, MR & Bernard, P Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia, (1997). 11, 1878–1886.
Cheson, BD, Cassileth, PA, Head, DR, Schiffer, CA, Bennett, JM, Bloomfield, CD, Brunning, R, Gale, RP, Grever, MR & Keating, MJ Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol, (1990). 8, 813–819.
Willemze, R, Sucia, S, Keating, S, Zittoun, R, de Witte, T, Belhabri, A, Amadori, S, Meloni, G, Rodts, P, Fibbe, WE & Mandelli, F The number of CD34 cells in cytokine mobilized peripheral blood stem cell grafts correlates with the risk of relapse; results of the EORTC-GIMEMA AML-10 trial. EBMT, (2001). (Abstr.)
Drach, D, Zhao, S, Drach, J, Mahadevia, R, Gattringer, C, Huber, H & Andreeff, M Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood, (1992). 80, 2729–2734.
Del Poeta, G, Stasi, R, Venditti, A, Suppo, G, Aronica, G, Bruno, A, Masi, M, Tabilio, A & Papa, G Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia, (1994). 8, 388–394.
van den Heuvel-Eibrink, MM, van der, HB, te Boekhorst, PA, Pieters, R, Schoester, M, Lowenberg, B & Sonneveld, P MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. Br J Haematol, (1997). 99, 76–83.
San Miguel, JF, Martinez, A, Macedo, A, Vidriales, MB, Lopez-Berges, C, Gonzalez, M, Caballero, D, Garcia-Marcos, MA, Ramos, F, Fernandez-Calvo, J, Calmuntia, MJ, Diaz-Mediavilla, J & Orfao, A Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood, (1997). 90, 2465–2470.
Campos, L, Rouault, JP, Sabido, O, Oriol, P, Roubi, N, Vasselon, C, Archimbaud, E, Magaud, JP & Guyotat, D High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood, (1993). 81, 3091–3096.
Maung, ZT, MacLean, FR, Reid, MM, Pearson, AD, Proctor, SJ, Hamilton, PJ & Hall, AG The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br J Haematol, (1994). 88, 105–109.
Galmarini, CM, Graham, K, Thomas, X, Calvo, F, Rousselot, P, El Jafaari, A, Cros, E, Mackey, JR & Dumontet, C Expression of high Km 5′-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood, (2001). 98, 1922–1926.
Macedo, A, San Miguel, JF, Vidriales, MB, Lopez-Berges, MC, Garcia-Marcos, MA, Gonzalez, M, Landolfi, C & Orfao, A Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease. J Clin Pathol, (1996). 49, 15–18.
Baer, MR, Stewart, CC, Dodge, RK, Leget, G, Sule, N, Mrozek, K, Schiffer, CA, Powell, BL, Kolitz, JE, Moore, JO, Stone, RM, Davey, FR, Carroll, AJ, Larson, RA & Bloomfield, CD High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood, (2001). 97, 3574–3580.
Kokenberg, E, Sonneveld, P, Sizoo, W, Hagenbeek, A & Lowenberg, B Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia. J Clin Oncol, (1988). 6, 802–812.
Gessner, T, Preisler, HD, Azarnia, N, Bolanowska, W, Vogler, WR, Grunwald, H, Joyce, R & Goldberg, J Plasma levels of daunorubicin metabolites and the outcome of ANLL therapy. Med Oncol Tumor Pharmacother, (1987). 4, 23–31.
Acknowledgements
We want to thank Drs Arne de Kreuk and Abel Thijs for their contribution to the statistical analyses, Gitta Evertse for helping to examine clinical data and Prof Dr Theo de Witte for his valuable suggestions.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Feller, N., Schuurhuis, G., van der Pol, M. et al. High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome. Leukemia 17, 68–75 (2003). https://doi.org/10.1038/sj.leu.2402781
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402781
Keywords
This article is cited by
-
Early response evaluation by single cell signaling profiling in acute myeloid leukemia
Nature Communications (2023)
-
Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects
Bone Marrow Transplantation (2015)
-
High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT
Bone Marrow Transplantation (2015)
-
Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT
Bone Marrow Transplantation (2014)
-
Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting
Blood Cancer Journal (2013)